E-Articles - Finance

Remember the last time you bought a stock or mutual fund? If you are like most investors the equity was recommended by your broker o

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

r a friend. You did research and received copious pieces of paper praising its attributes.

Because there are thousands of stocks an

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

also thousands of mutual funds it is difficult to know where to look. Most folks like to buy stock in a company they think they kn

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

w. You did notice I said “think” they know. Almost any of the papers about the company are pretty well dated by the time you see th

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

m especially those pretty full color slick sheets and binders.

Keep gathering information and even buying a report from Morningstar

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

They are the nexus of financial information. Some of it may be 6 months old, but you have no way of knowing that. Just about every

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

hing you can get your hands on will give praise to this wonderful company. It must be good. Right?

You are convinced so you buy som

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

stock. The trap is sprung. After a while the stock price hasn’t changed much so you hang in there. Then it begins to head down. Yo

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

continue to hold it. It will come back. That’s what the broker said, but this little hummer continues to slowly erode. You are beg

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

nning to have doubts about it, but still no thought of selling. No point in looking at it every day. Just put it away.

There was a

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

time when you could have sold out for a small loss, but you didn’t. Why didn’t you take the small loss instead of being saddled wit

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

h a loss of more than 50%? And it still doesn’t look good.

When anyone becomes involved with something the very act of observation

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

akes the observer part of the observed. That is a basic physics principle. When an investor does research he starts binding himself

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

to that stock. The more it is studied the tighter the bond. The bond is cemented when the purchase is made. Now a new thought proce

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

s enters when the stock does not perform as expected. The investor will not admit he was wrong. He refuses to sell.

Almost every in

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

estor thinks of where to buy and never thinks of protecting his cash. The professional trader looks first to the risk with an exit

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

trategy should he be wrong. Being right takes care of itself. Working with a profit base is easier than trying to hold to a losing

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

osition.

The professional looks at his cash as inventory. He can’t allow it to slip away so he does everything possible to protect

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

t from loss. His thought process is almost exactly opposite that of the amateur. Small losses don’t bother him.

Until the average

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

nvestor learns to disconnect from his psychological inhibitions and use an exit strategy he will not make money in the stock market

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.e-article.org.ua/article/103870/e-article-Why-You-Dont-Make-Money-In-The-Stock-Market.html">Why You Don't Make Money In The Stock Market</a>

BB link (for phorums):
[url=http://www.e-article.org.ua/article/103870/e-article-Why-You-Dont-Make-Money-In-The-Stock-Market.html]Why You Don't Make Money In The Stock Market[/url]

If you want an email campaign to succeed, you don`t want to offend anyone when sending your messages. Turn off a consumer with your email and you can be sure they`ll tune out your message. Don`t let this happen to you!

A top ten ranking in Google or Yahoo! can mean the difference between your business's success or failure. This article examines how to contact a great SEO company that will do the critical search engine submission process that will work best for you.

Tags

Links

E-Articles - Why You Don't Make Money In The Stock Market

Related Articles: